Medical information Clinical review pending

Cytogenetics

Oncomine Comprehensive Panel, Oncomine Tumor Mutation Burden (TMB), MSI, PDL1

A comprehensive genetic test analyzing tumor tissue and blood to identify mutations, TMB, MSI, and PDL1 expression, aiding in personalized cancer treatment decisions.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question

Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample: Paraffin-embedded tumor tissue block and peripheral blood sample (EDTA Vacutainer tube, 3ml). Confirm specific requirements with the laboratory before booking.
Results: Approximately 2-3 weeks. Confirm exact turnaround time with the laboratory before booking.
Preparation: No specific patient preparation is required. A doctor's prescription is necessary. Please note that this test may not be suitable for individuals undergoing surgery, pregnant women, or those planning immediate international travel. Consult your doctor.

Test priceKSh 240,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Oncomine Comprehensive Panel, Oncomine Tumor Mutation Burden (TMB), MSI, PDL1 test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

Insurer or scheme name & policy / member number
A clinician's request / prescription for the test
Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

Full name *

Mobile number *

+254

Insurer or scheme

Policy / member number (optional)

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

WhatsApp the claims team Call us

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

✓Diagnosis and classification of various cancer types.
✓Guiding treatment decisions for patients with advanced or metastatic cancer.
✓Identifying patients potentially eligible for targeted therapies.
✓Assessing suitability for immunotherapy.
✓Prognosis determination.
✓Identifying potential clinical trial eligibility.

In plain language

What this test helps you understand

This test provides comprehensive genomic information about a tumor, helping oncologists understand its specific characteristics. It aids in selecting the most appropriate targeted therapies or immunotherapies, predicting potential response to treatment, and identifying patients who might be eligible for clinical trials. The results can guide personalized cancer management strategies.

The Oncomine Comprehensive Panel, Tumor Mutation Burden (TMB), Microsatellite Instability (MSI), and PD-L1 Expression test is an advanced genetic analysis used in cancer care. This test examines tumor tissue and peripheral blood samples to identify specific genetic alterations within the tumor. Understanding these alterations, including the overall mutation load (TMB), DNA stability (MSI), and the presence of the PD-L1 protein, provides crucial information for oncologists. This information helps guide treatment strategies, potentially identifying patients who may benefit from targeted therapies or immunotherapy. This test is a valuable tool for developing personalized cancer treatment plans. Results are typically available within 2-3 weeks. Confirm with the laboratory before booking.

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

Speak with us

We check the test and answer your questions before collection.

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

Understand your report

A counselor helps you understand the result and the next steps.

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →

PreparationNo specific patient preparation is required. A doctor's prescription is necessary. Please note that this test may not be suitable for individuals undergoing surgery, pregnant women, or those planning immediate international travel. Consult your doctor.

SampleParaffin-embedded tumor tissue block and peripheral blood sample (EDTA Vacutainer tube, 3ml). Confirm specific requirements with the laboratory before booking.

MethodologyNext-Generation Sequencing (NGS) is typically used for the comprehensive mutation panel, TMB, and MSI analysis. Immunohistochemistry (IHC) is commonly used for PD-L1 expression assessment. Confirm specific methodologies with the laboratory before booking.

PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.

This test analyzes specific genetic mutations and markers. It may not detect all possible genetic alterations. Results should be interpreted in the context of the patient's clinical history, pathology reports, and other diagnostic findings. Confirm with the laboratory before booking.

Read your report

What common result terms mean

TermPlain-language meaning

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.

NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.

VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.

Questions people ask

Frequently asked questions

TMB measures the total number of mutations within a tumor's DNA. A higher TMB can sometimes indicate a better response to certain immunotherapies.

MSI stands for Microsatellite Instability. It assesses how stable the tumor's DNA is. High MSI (MSI-H) tumors may respond differently to treatments compared to stable (MSS) tumors.

PD-L1 is a protein found on some cancer cells. Its presence can affect how the immune system interacts with the tumor and may influence the effectiveness of immunotherapy.

Your oncologist or healthcare provider will interpret the results in the context of your specific medical condition and discuss the implications with you.

Yes, a doctor's prescription is required to order this test.

This test is generally not recommended for pregnant women. Please consult your doctor.

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

ACMG/AMP technical standards for sequence variant interpretation
ClinGen curation and gene–disease validity frameworks where applicable
LOINC-coded reporting for interoperable results
ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

Last updated: September 27, 2026
Medical review: not yet completed
Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →

Chat on WhatsApp